Xencor Inc (XNCR) Stock Price & Analysis
Xencor Inc (XNCR) rose 4.21% to USD 11.89 as of June 10, 2026 at 02:27 UTC, according to Nexqual real-time market data.
XNCR last closed at USD 11.41; the session ranged USD 11.57–12.04 on volume of 1,000,204 shares. Market capitalization is $881.54M, with a 52-week range of USD 6.92–18.69 (NGM). Source: Nexqual, June 10, 2026 at 02:27 UTC.
Key Statistics (as of June 10, 2026 at 02:27 UTC)
| Price | USD 11.89 |
|---|---|
| Change | ▲ 4.21% (up) |
| Previous Close | USD 11.41 |
| Open | USD 11.61 |
| Day Range | USD 11.57 – 12.04 |
| 52-Week Range | USD 6.92 – 18.69 |
| Volume | 1,000,204 shares |
| Market Cap | $881.54M |
| Exchange | NGM |
Technical Analysis (XNCR)
Nexqual's technical model rates XNCR "SELL" based on 2 bullish and 4 bearish signals across 124 daily candles, as of June 10, 2026 at 02:27 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 49.94 (neutral) |
| vs SMA50 | Below (USD 12.15) |
| MACD | -0.13 (negative) |
Analyst Ratings (XNCR)
Wall Street analysts rate XNCR "None" based on 12 analysts, with a mean price target of USD 28.5 (range USD 14–43), per Nexqual as of June 10, 2026 at 02:27 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 28.5 |
| High Target | USD 43 |
| Low Target | USD 14 |
| Buy / Hold / Sell | 12 / 2 / 0 |
Earnings (XNCR)
| Next Earnings Date | 2026-08-05 |
|---|---|
| EPS Estimate | USD -0.83 |
| Revenue Estimate | $18.97M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.71 vs est -0.75 ▼ miss |
| 2025-12-31 | USD -0.09 vs est -0.58 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.7 ▲ beat |
| 2025-06-30 | USD -0.41 vs est -0.71 ▲ beat |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Financials & Fundamentals (XNCR)
| Total Revenue | $97.36M |
|---|---|
| Revenue Growth (YoY) | -86.20% |
| Gross Margin | -152.18% |
| Operating Margin | -1724.14% |
| Profit Margin | -177.10% |
| ROE | -29.84% |
| Debt / Equity | 33.97 |
| Current Ratio | 6.57 |
| Total Cash | $444.95M |
| Total Debt | $175.16M |
| Free Cash Flow | $-76.89M |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Financial Health Score (XNCR)
Nexqual rates Xencor Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 02:27 UTC.
| Growth | Solid — Revenue +14% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $445M cash vs $175M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$77M, burning cash |
| Efficiency | Critical — ROE -30%, ROA -16.2% |
Ownership (XNCR)
| Insider Ownership | +1.18% |
|---|---|
| Institutional Ownership | +115.46% |
| Shares Outstanding | 74.14M |
| Float | 54.48M |
| Short % of Float | +20.88% |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
Leadership (XNCR)
Xencor Inc is led by Bassil I. Dahiyat (age 55), Co-Founder, CEO, President & Director, per Nexqual as of June 10, 2026 at 02:27 UTC.
| Co-Founder, CEO, President & Director | Bassil I. Dahiyat (age 55) |
|---|---|
| Senior VP & CFO | Bart Jan Cornelissen (age 47) |
| Executive VP of Research & Chief Scientific Officer | John R. Desjarlais (age 61) |
| Associate Director and Head of Corporate Communications & Investor Relations | Charles Liles |
| Senior VIce President of Human Resources | Jennifer Sandoz |
Major Backers & Investors (XNCR)
Notable institutional backers of Xencor Inc include Primecap Management Company, PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund, BVF Inc., according to Nexqual as of June 10, 2026 at 02:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Primecap Management Company | 13.94% |
| PRIMECAP Odyssey Funds-PRIMECAP Odyssey Aggressive Growth Fund | 12.94% |
| BVF Inc. | 9.62% |
| RTW Investments LP | 9.14% |
| RA Capital Management, L.P. | 6.61% |
| TCG Crossover Management, LLC | 3.31% |
| EcoR1 Capital, LLC | 2.94% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 26.6% |
| Vanguard Group | 14.12% |
| State Street | 8.01% |
Source: Nexqual, June 10, 2026 at 02:27 UTC.
From Xencor Inc's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Drug Development Process In the United States, the FDA regulates drugs and biologic products under the Federal Food, Drug and Cosmetic Act (FDCA), its implementing regulations, and other laws including, in the case of biologics, the Public Health Service Act.
- Biologics require the submission of a Biologics License Application (BLA) to the FDA and approval of the BLA by the FDA before marketing in the United States.
- Protect and expand our intellectual property portfolio We seek to protect our proprietary XmAb technologies and XmAb drug candidates by filing and prosecuting patents in the United States and other jurisdictions.
- Where appropriate, we pursue the expansion and extension of patent coverage for our proprietary and partnered programs incorporating our XmAb technologies. 5 D.
Partnerships
- Master Services Agreement with Kapadi (formerly OncoBay Clinical, Inc.) In August 2023, we entered into a master services agreement with OncoBay Clinical, Inc., now known as Kapadi, for CROs services supporting clinical trial management and development (including site selection, study design, site monitoring, management and training, and patient selection).
- License Agreement with BIO-TECHNE In April 2021, we entered into a non-exclusive license agreement with BIO-TECHNE for a recombinant monoclonal antibody reactive with human CLDN6, which is used in our XmAb541 program.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MGNX | MacroGenics, Inc. | USD 3.91 | ▲ 0% |
| ENTA | Enanta Pharmaceuticals, Inc. | USD 11.35 | ▲ 0.62% |
| ANAB | AnaptysBio, Inc. | USD 51.63 | ▲ 2.5% |
| RGNX | REGENXBIO Inc. | USD 6.34 | ▲ 4.28% |
| TBPH | Theravance Biopharma, Inc. | USD 16.49 | ▲ 1.23% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 02:27 UTC. This page is informational and not investment advice.